Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular, Intradermal and Transcutaneous Routes

Inclusion Criteria: 1. Men and women aged between 18 and 45 years on the day of screening 2. BMI between 19-28 3. Available for follow-up for the duration of the study (\~6 months from screening) 4. Willing and able to give written informed consent 5. At low risk of HIV and willing to remain so for the duration of the study defined as: * no history of injecting drug use in the previous ten years * no gonorrhoea or syphilis in the last six months * no high risk partner (e.g. injecting drug use, HIV positive partner) either currently or within the past six months * no unprotected anal intercourse in the last six months, outside a relationship with a regular partner known to be HIV negative * no unprotected vaginal intercourse in the last six months outside a relationship with a regular known/presumed HIV negative partner 6. Willing to undergo a HIV test 7. Willing to undergo a genital infection screen 8. If heterosexually active female, using an effective method of contraception with partner (combined oral contraceptive pill; injectable or implanted contraceptive; consistent record with condoms if using these; physiological or anatomical sterility in self or partner) from 14 days prior to the first vaccination until 4 months after the last, and willing to undergo urine pregnancy tests prior to each vaccination 9. If heterosexually active male, using an effective method of contraception with their partner from the first day of vaccination until 4 months after the last vaccination 10. Agree to abstain from donating blood for three months after the end of their participation in the trial, or longer if necessary 11. Registered with a GP for at least the past three months 12. Satisfactory response received from GP before randomisation Exclusion Criteria: 1. Pregnant or lactating 2. Use of any topical treatment on the injection or application site within the last four weeks 3. No UV tanning sessions or strong sun exposure within four weeks prior to the study and a willingness to avoid these during the study period. 4. Excessive terminal hair growth on the investigational skin areas (to be assessed by reference to a photograph which will be available during screening visit. 5. Individuals in which a skin-fold measurement (cutaneous and subcutaneous tissue) of the upper right or left thigh exceeds 40 mm. 6. Clinically relevant abnormality on history or examination including * history of grand-mal epilepsy, seizure disorder or any history of prior seizure * history of syncope or fainting episodes within 1 year of study entry. * severe eczema * liver disease with inadequate hepatic function * any skin condition which may interfere with the trial assessment on the injection site * haematological, metabolic, gastrointestinal or cardio-pulmonary disorders including an abnormal ECG. * uncontrolled infection; toxic shock syndrome * autoimmune disease, immunodeficiency or use of immunosuppressives in preceding 3 months 7. Known hypersensitivity to any component of the vaccine formulations used in this trial, or a seafood allergy or have severe or multiple allergies to drugs or pharmaceutical agents 8. History of severe local or general reaction to vaccination defined as 1. local: extensive, indurated redness and swelling involving most of the antero-lateral thigh or the major circumference of the arm, not resolving within 72 hours 2. general: fever \>= 39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal oedema; collapse; convulsions or encephalopathy within 72 hours 9. Receipt of live attenuated vaccine within 60 days or other vaccine within 14 days of enrolment 10. Receipt of an experimental vaccine containing HIV antigens at any time in the past 11. Receipt of blood products or immunoglobin within 4 months of screening 12. Participation in another trial of a medicinal product, completed less than 30 days prior to enrolment 13. HIV 1 or 2 positive or indeterminate on screening 14. Positive for hepatitis B surface antigen, hepatitis C antibody or serology indicating active syphilis requiring treatment 15. Grade 1 or above routine laboratory parameters (see study specific tables - Appendix 3 for definitions). Hyperbilirubinaemia to be considered an exclusion criterion only when confirmed to be conjugated bilirubinaemia 16. Current use of any electronic stimulation device, such as cardiac demand pacemakers, automatic implantable cardiac defibrillator, nerve stimulators, or deep brain stimulators. 17. Presence of any surgical or traumatic metal implants at the sites of administration 18. Presence of an intrauterine device. 19. Unable to read and speak English to a fluency level adequate for the full comprehension of procedures required in participation and consent. 20. Unlikely to comply with protocol.